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background:  Transcatheter aortic valve replacement (TAVR) is now standard of care for patients with symptomatic aortic stenosis (AS) 
at extreme or high risk for surgery, yet opportunities for improvement in technology remain. The CoreValve Evolut R self-expanding TAV is 
fully repositionable to assure optimal valve positioning.
methods:  The CoreValve Evolut R Clinical Study was designed to assess the safety and clinical performance of the CoreValve Evolut R 
System (26 mm, 29 mm) in symptomatic high or extreme risk patients with AS (Heart Team assessment) enrolled at 6 centers in Australia, 
the United Kingdom, and New Zealand. The primary safety endpoints were the rate of all-cause mortality and the rate of any stroke at 30 
days. The primary clinical performance endpoints were device success (VARC II) and the percentage of patients with no more than mild 
aortic regurgitation at early post procedure.
results:  A total of 60 patients who met inclusion and exclusion criteria were enrolled and all received the Evolut R TAV. Mean age was 
82.8± 6.1 years, 66.7% women, 68.3% had New York Heart Association III or IV symptoms, and the mean STS-PROM was 7.3% ± 4.0%. 
Chronic lung disease was present in 43.3% of patients, and 26.7% had diabetes. There were 28.3% of patients with previous CABG, and 
36.7% had a history of atrial fibrillation. The majority of patients (68.3%) were considered frail.
Conclusion:  Early experience with the CoreValve Evolut R bioprosthesis will be reported at the time of the meeting.
